Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Genetic counseling for DAPK1 mutation in a chronic lymphocytic leukemia family.

Lynch HT, Ferrara KM, Weisenburger DD, Sanger WG, Lynch JF, Thomé SD.

Cancer Genet Cytogenet. 2008 Oct 15;186(2):95-102. doi: 10.1016/j.cancergencyto.2008.06.014.

2.

Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C.

Cell. 2007 Jun 1;129(5):879-90.

3.

Germline allele-specific expression of DAPK1 in chronic lymphocytic leukemia.

Wei QX, Claus R, Hielscher T, Mertens D, Raval A, Oakes CC, Tanner SM, de la Chapelle A, Byrd JC, Stilgenbauer S, Plass C.

PLoS One. 2013;8(1):e55261. doi: 10.1371/journal.pone.0055261. Epub 2013 Jan 28.

4.

Chronic lymphocytic leukemia: keeping cell death at bay.

Debatin KM.

Cell. 2007 Jun 1;129(5):853-5.

5.

Quantitative analyses of DAPK1 methylation in AML and MDS.

Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, Blagitko-Dorfs N, Hiller J, Wilop S, Brümmendorf TH, Galm O, Platzbecker U, Byrd JC, Döhner K, Döhner H, Lübbert M, Plass C.

Int J Cancer. 2012 Jul 15;131(2):E138-42. doi: 10.1002/ijc.26429. Epub 2011 Nov 28.

6.

Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia.

Qian J, Wang YL, Lin J, Yao DM, Xu WR, Wu CY.

Eur J Haematol. 2009 Feb;82(2):119-23. doi: 10.1111/j.1600-0609.2008.01178.x. Epub 2008 Nov 6.

PMID:
19018866
7.

Critical role for transcription factor C/EBP-beta in regulating the expression of death-associated protein kinase 1.

Gade P, Roy SK, Li H, Nallar SC, Kalvakolanu DV.

Mol Cell Biol. 2008 Apr;28(8):2528-48. doi: 10.1128/MCB.00784-07. Epub 2008 Feb 4.

8.

Death-associated protein kinase 1 variation and Parkinson's disease.

Dachsel JC, Wider C, Vilariño-Güell C, Aasly JO, Rajput A, Rajput AH, Lynch T, Craig D, Krygowska-Wajs A, Jasinska-Myga B, Opala G, Barcikowska M, Czyzewski K, Wu RM, Heckman MG, Uitti RJ, Wszolek ZK, Farrer MJ, Ross OA.

Eur J Neurol. 2011 Aug;18(8):1090-3. doi: 10.1111/j.1468-1331.2010.03255.x. Epub 2010 Nov 30.

PMID:
21749573
9.

Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes.

Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A.

Br J Haematol. 2007 Dec;139(5):744-52. Epub 2007 Oct 24. Review.

PMID:
17961188
10.

Aberrant methylation of death-associated protein kinase 1 CpG islands in myelodysplastic syndromes.

Wu X, Liu W, Tian Y, Xiao M, Wu Y, Li C.

Acta Haematol. 2011;125(4):179-85. doi: 10.1159/000322593. Epub 2011 Jan 4.

PMID:
21212658
11.

Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.

Ahmed IA, Pusch CM, Hamed T, Rashad H, Idris A, El-Fadle AA, Blin N.

Cancer Genet Cytogenet. 2010 Jun;199(2):96-100. doi: 10.1016/j.cancergencyto.2010.02.007.

PMID:
20471512
12.

Effects of ILTG on DAPK1 promoter methylation in colon and leukemia cancer cell lines.

Zorko BA, Pérez LB, De Blanco EJ.

Anticancer Res. 2010 Oct;30(10):3945-50.

PMID:
21036707
13.

DAPK1 is associated with FTD and not with Alzheimer's disease.

Tedde A, Piaceri I, Bagnoli S, Lucenteforte E, Piacentini S, Sorbi S, Nacmias B.

J Alzheimers Dis. 2012;32(1):13-7.

PMID:
22785394
14.

Association of DAPK1 genetic variations with Alzheimer's disease in Han Chinese.

Wu ZC, Zhang W, Yu JT, Zhang Q, Tian Y, Lu RC, Yu NN, Chi ZF, Tan L.

Brain Res. 2011 Feb 16;1374:129-33. doi: 10.1016/j.brainres.2010.12.036. Epub 2010 Dec 16.

PMID:
21167819
15.

Methylation of DAPK1 promoter: frequent but not an adverse prognostic factor in myelodysplastic syndrome.

Qian J, Yao DM, Lin J, Wang YL, Han LX, Xu WR, Wu CY.

Int J Lab Hematol. 2010 Feb;32(1 Pt 2):74-81. doi: 10.1111/j.1751-553X.2008.01131.x. Epub 2009 Jan 2.

PMID:
19196380
16.

Genetic counseling in hereditary nonpolyposis colorectal cancer: an extended family with MSH2 mutation.

Lynch HT, Lemon S, Smyrk T, Franklin B, Karr B, Lynch J, Slominski-Caster S, Murphy P, Connolly C.

Am J Gastroenterol. 1996 Dec;91(12):2489-93.

PMID:
8946971
17.

Alterations in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in prostate carcinomas.

Kilinc D, Ozdemir O, Ozdemir S, Korgali E, Koksal B, Uslu A, Gultekin YE.

DNA Cell Biol. 2012 May;31(5):826-32. doi: 10.1089/dna.2011.1431. Epub 2011 Dec 2.

PMID:
22136354
18.

Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy.

Lynch HT, Kaurah P, Wirtzfeld D, Rubinstein WS, Weissman S, Lynch JF, Grady W, Wiyrick S, Senz J, Huntsman DG.

Cancer. 2008 Jun 15;112(12):2655-63. doi: 10.1002/cncr.23501.

19.

DAPk1 inhibits NF-κB activation through TNF-α and INF-γ-induced apoptosis.

Yoo HJ, Byun HJ, Kim BR, Lee KH, Park SY, Rho SB.

Cell Signal. 2012 Jul;24(7):1471-7. doi: 10.1016/j.cellsig.2012.03.010. Epub 2012 Mar 23.

PMID:
22465880
20.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171

Supplemental Content

Support Center